SOURCE: Patheon

Patheon

July 07, 2014 10:44 ET

Patheon to Showcase Integrated Development Services at Controlled Release Society's Annual Meeting

DURHAM, NC--(Marketwired - July 07, 2014) - Patheon, the pharmaceutical services business owned by DPx Holdings B.V., will showcase the company's fully integrated early development services at the 41st Annual Meeting & Exposition of the Controlled Release Society (CRS) at The Hilton Chicago in Chicago, Ill., from Saturday, July 12 to Wednesday, July 16.

Solomon Kirsh, Arasu Kondappan, Enrico Corona, Paul Sabo and Sateesh Sathigari will represent Patheon in leading five out of the nearly 750 poster and podium presentations offered at the CRS Annual Meeting & Exposition.

Solomon Kirsh, chemist at Patheon, will present a poster detailing rapid HPLC method supporting renin inhibitor enteric coated beads formulation development; Arasu Kondappan, pharmaceutical formulation scientist at Patheon, will discuss the formulation of controlled release orally disintegrating tablets of water soluble compounds; and Enrico Corona, manager of formulation and process development at Patheon, will present a poster on the development of the manufacturing process for a parenteral depot formulation in the situ precipitation.

Posters such as those presented by experts at Patheon are used at the CRS Annual Meeting & Exposition to display scientific achievements and the newest technologies.

Podium presentations will include Stepwise Approach to Preformulation and Formulation Development to Maximize Clinical Success presented by Paul Sabo, senior specialist formulation at Patheon, and Production of Nano/Micro Drug Particles by Supercritical Fluid Technology led by Sateesh Sathigari, scientist of formulation and process development at Patheon.

Patheon, a gold sponsor of this year's meeting, will also have a representative stationed at booth number 403 throughout the exposition.

The CRS Annual Meeting & Exposition is a professional, scientific meeting that will have more than 1,300 international scientists who work in drug delivery, consumer and diversified products in attendance. The theme of this year's CRS Annual Meeting & Exposition will be "Translation of Delivery Technology: Innovation to Commercialization," and feature technology forums, soapbox sessions, industry roundtables and workshops where attendees can learn about pharmaceutical companies' research, products and technology, and network with industry experts.

For more information, visit www.controlledreleasesociety.org/meetings/annual/Pages/default.aspx.

About DPx Holdings B.V.
DPx Holdings B.V. is the privately held parent company of the Patheon, DSM Fine Chemicals and Banner Life Sciences businesses. The company is a leading provider of CDMO services, pharmaceutical products and products for other industries. DPx Holdings B.V. was founded in 2014 as a result of a deal between JLL Partners and Royal DSM. With a global headquarters in Durham, N.C., DPx Holdings B.V. has a footprint of more than 20 locations across North America, Europe, Latin America and Australia with more than 8,000 employees. DPx Holdings B.V. offers customers unsurpassed quality, integrated offerings and value through these three business units. For more information visit www.patheon.com/DPx.

About Patheon
Patheon is a leading provider of contract development and commercial manufacturing (CDMO) services to the global pharmaceutical industry for a full array of solid and sterile dosage forms. Patheon, a DPx Holdings B.V. business unit, encompasses the combined CMO capabilities and pharmaceutical product development services (PDS), as well as the Biosolutions and Biologics (BIO) business. For more information visit www.patheon.com

Contact Information